Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach

Kingkan Sanphanya, Suvara K. Wattanapitayakul, Suwadee Phowichit, Valery V. Fokin, Opa Vajragupta

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We report a novel VEGFR-2 inhibitor, developed by the back-to-front approach. Docking experiments indicated that the 3-chloromethylphenylurea motif of the lead compound occupied the back pocket of VEGFR-2 kinase. An attempt was made to enhance the binding affinity of 1 by expanding the structure to access the front pocket using a triazole linker. A library of 1,4-(disubstituted)-1H-1, 2,3-triazoles were screened in silico, and one compound (VH02) was identified with an IC50 against VEGFR-2 of 0.56 μM. VH02 showed antiangiogenic effects, inhibiting tube formation in HUVEC cells (EA.hy926) at 0.3 μM, 13 times lower than its cytotoxic dose. These enzymatic and cellular activities suggest that VH02 has potential as a lead for further optimization.

Original languageEnglish
Pages (from-to)2962-2967
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume23
Issue number10
DOIs
Publication statusPublished - 15 May 2013
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Triazoles
Phosphotransferases
Lead compounds
Human Umbilical Vein Endothelial Cells
Computer Simulation
Inhibitory Concentration 50
Libraries
Experiments
Lead

Keywords

  • VEGFR-2 KDR VEGFR-2 inhibitor Molecular modeling Antiangiogenesis 1,4-Disubstituted 1,2,3-triazoles CuAAC reaction

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Sanphanya, K., Wattanapitayakul, S. K., Phowichit, S., Fokin, V. V., & Vajragupta, O. (2013). Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorganic and Medicinal Chemistry Letters, 23(10), 2962-2967. https://doi.org/10.1016/j.bmcl.2013.03.042

Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. / Sanphanya, Kingkan; Wattanapitayakul, Suvara K.; Phowichit, Suwadee; Fokin, Valery V.; Vajragupta, Opa.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 10, 15.05.2013, p. 2962-2967.

Research output: Contribution to journalArticle

Sanphanya, K, Wattanapitayakul, SK, Phowichit, S, Fokin, VV & Vajragupta, O 2013, 'Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach', Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 10, pp. 2962-2967. https://doi.org/10.1016/j.bmcl.2013.03.042
Sanphanya K, Wattanapitayakul SK, Phowichit S, Fokin VV, Vajragupta O. Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. Bioorganic and Medicinal Chemistry Letters. 2013 May 15;23(10):2962-2967. https://doi.org/10.1016/j.bmcl.2013.03.042
Sanphanya, Kingkan ; Wattanapitayakul, Suvara K. ; Phowichit, Suwadee ; Fokin, Valery V. ; Vajragupta, Opa. / Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. In: Bioorganic and Medicinal Chemistry Letters. 2013 ; Vol. 23, No. 10. pp. 2962-2967.
@article{07b85247e1174ad4906263b7b2fe7b6f,
title = "Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach",
abstract = "We report a novel VEGFR-2 inhibitor, developed by the back-to-front approach. Docking experiments indicated that the 3-chloromethylphenylurea motif of the lead compound occupied the back pocket of VEGFR-2 kinase. An attempt was made to enhance the binding affinity of 1 by expanding the structure to access the front pocket using a triazole linker. A library of 1,4-(disubstituted)-1H-1, 2,3-triazoles were screened in silico, and one compound (VH02) was identified with an IC50 against VEGFR-2 of 0.56 μM. VH02 showed antiangiogenic effects, inhibiting tube formation in HUVEC cells (EA.hy926) at 0.3 μM, 13 times lower than its cytotoxic dose. These enzymatic and cellular activities suggest that VH02 has potential as a lead for further optimization.",
keywords = "VEGFR-2 KDR VEGFR-2 inhibitor Molecular modeling Antiangiogenesis 1,4-Disubstituted 1,2,3-triazoles CuAAC reaction",
author = "Kingkan Sanphanya and Wattanapitayakul, {Suvara K.} and Suwadee Phowichit and Fokin, {Valery V.} and Opa Vajragupta",
year = "2013",
month = "5",
day = "15",
doi = "10.1016/j.bmcl.2013.03.042",
language = "English",
volume = "23",
pages = "2962--2967",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach

AU - Sanphanya, Kingkan

AU - Wattanapitayakul, Suvara K.

AU - Phowichit, Suwadee

AU - Fokin, Valery V.

AU - Vajragupta, Opa

PY - 2013/5/15

Y1 - 2013/5/15

N2 - We report a novel VEGFR-2 inhibitor, developed by the back-to-front approach. Docking experiments indicated that the 3-chloromethylphenylurea motif of the lead compound occupied the back pocket of VEGFR-2 kinase. An attempt was made to enhance the binding affinity of 1 by expanding the structure to access the front pocket using a triazole linker. A library of 1,4-(disubstituted)-1H-1, 2,3-triazoles were screened in silico, and one compound (VH02) was identified with an IC50 against VEGFR-2 of 0.56 μM. VH02 showed antiangiogenic effects, inhibiting tube formation in HUVEC cells (EA.hy926) at 0.3 μM, 13 times lower than its cytotoxic dose. These enzymatic and cellular activities suggest that VH02 has potential as a lead for further optimization.

AB - We report a novel VEGFR-2 inhibitor, developed by the back-to-front approach. Docking experiments indicated that the 3-chloromethylphenylurea motif of the lead compound occupied the back pocket of VEGFR-2 kinase. An attempt was made to enhance the binding affinity of 1 by expanding the structure to access the front pocket using a triazole linker. A library of 1,4-(disubstituted)-1H-1, 2,3-triazoles were screened in silico, and one compound (VH02) was identified with an IC50 against VEGFR-2 of 0.56 μM. VH02 showed antiangiogenic effects, inhibiting tube formation in HUVEC cells (EA.hy926) at 0.3 μM, 13 times lower than its cytotoxic dose. These enzymatic and cellular activities suggest that VH02 has potential as a lead for further optimization.

KW - VEGFR-2 KDR VEGFR-2 inhibitor Molecular modeling Antiangiogenesis 1,4-Disubstituted 1,2,3-triazoles CuAAC reaction

UR - http://www.scopus.com/inward/record.url?scp=84876669366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876669366&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.03.042

DO - 10.1016/j.bmcl.2013.03.042

M3 - Article

VL - 23

SP - 2962

EP - 2967

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 10

ER -